Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16349729 | 0.87 | GAA (0.56) | ALDH1A1KMT2AMEN1MAPTL3MBTL1 | |
| SCHEMBL3056874 | 0.87 | KMT2A (0.71) | ALDH1A1KMT2AMEN1MAPTL3MBTL1 | |
| SCHEMBL8525398 | 0.84 | ALDH1A1 (0.59) | ALDH1A1KMT2AMEN1MAPTL3MBTL1 | |
| SCHEMBL183463 | 0.84 | ALDH1A1 (0.59) | ALDH1A1KMT2AMEN1MAPTL3MBTL1 | |
| SCHEMBL13130712 | 0.84 | ALDH1A1 (0.59) | ALDH1A1KMT2AMEN1MAPTL3MBTL1 | |
| SCHEMBL97001 | 0.83 | KMT2A (0.68) | ALDH1A1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL1867492 | 0.83 | ALDH1A1 (0.61) | ALDH1A1KMT2AMEN1MAPTL3MBTL1 | |
| SCHEMBL20438786 | 0.82 | ALDH1A1 (0.53) | ALDH1A1KMT2AMEN1MAPTL3MBTL1 | |
| SCHEMBL10058715 | 0.82 | MEN1 (0.66) | ALDH1A1KMT2AMEN1MAPTL3MBTL1 | |
| SCHEMBL4486771 | 0.82 | KMT2A (0.66) | ALDH1A1KMT2AMEN1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025056724-A1 | IMINOAMIDE-TYPE COMPOUNDS AS LIGANDS FOR COPPER-CATALYZED COUPLING REACTIONS OF (HETERO)ARYL HALIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2025-03-20 | — | — | WO | disclosed |
| US-20230348365-A1 | COMPOUNDS FOR TREATING INFECTIONS | ARTS & CIÈNCIES EUROPA (AD) | 2023-11-02 | — | — | US | disclosed |
| WO-2023109926-A1 | SPIROOXINDOLE COMPOUND AND USE THEREOF IN PREPARATION OF PROTEASE INHIBITOR AS ANTIVIRAL DRUG | 南京药石科技股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-8426359-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-23 | — | — | US | disclosed |
| US-8314141-B2 | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314141-B2 | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2314598-A1 | Inhibitors of Hepatitis C virus NS3 serine protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20110059018-A1 | COVALENTLY BINDING IMAGING PROBES | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | disclosed |
| US-7605264-B2 | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-20 | — | — | US | disclosed |
| US-20070270453-A1 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-22 | — | — | US | disclosed |
| US-20070270453-A1 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-22 | — | — | US | disclosed |
| US-7253283-B2 | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253283-B2 | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1206241-A1 | METHODS OF LIGHTENING KERATINOUS TISSUE BY TOPICAL APPLICATION OF OXIME COMPOUND CONTAINING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001013882-A1 | METHODS OF LIGHTENING KERATINOUS TISSUE BY TOPICAL APPLICATION OF OXIME COMPOUND CONTAINING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2001-03-01 | — | — | WO | disclosed |
| US-5364617-A | Protection from solar radiation, chelate with iron in body and reduce its ability to catalyze formation of oxygen free radicals | THE PROCTER & GAMBLE COMPANY (US) | 1994-11-15 | — | — | US | disclosed |
| EP-0611301-A1 | CHELATOR COMPOSITIONS COMPRISING OXIME COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1994-08-24 | — | — | EP | disclosed |
| EP-0611301-A4 | CHELATOR COMPOSITIONS COMPRISING OXIME COMPOUNDS. | PROCTER & GAMBLE (US) | 1993-03-01 | — | — | EP | disclosed |
| WO-1991016034-A1 | CHELATOR COMPOSITIONS COMPRISING OXIME COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348365-A1 | COMPOUNDS FOR TREATING INFECTIONS | DPM1, TREH, MPO | ALDH1A1 262/4885KMT2A 1543/4885MEN1 600/4885 |
| US-20110059018-A1 | COVALENTLY BINDING IMAGING PROBES | CTSV, CTSL, CTSE | ALDH1A1 1016/4885KMT2A 3834/4885MEN1 1935/4885 |
| US-20070270453-A1 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFRKB, NFKBIA, NFKB1 | ALDH1A1 3536/4885KMT2A 3366/4885MEN1 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.